Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab Plus Bendamustine in Previously Untreated CLL
NCT02320487Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2015
- Primary completion
- Nov 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in chronic lymphocytic leukemia (CLL), sponsored by Genentech. Started Mar 2015; status: completed.
02
Drugs
obinutuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02320487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02320487.